Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/PEPG/vs peers

PEPGPepGen Inc.vs its industry peers

A metric-by-metric comparison of PepGen Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.

Full peer comparison
Peers: same SEC industry
CompanyMarket capP/E (TTM)P/BP/SRevenue growth (YoY)Earnings growth (YoY)EBIT marginROEROICPiotroski F1y total returnDividend yield
PEPGPepGen Inc.This$162M#8—1.4x#8——0.4%#8—-75.0%#12——-49.9%#9—
UPBUpstream Bio, Inc.$176M#1—0.6x#361.6x#420.4%#2-128.4%#13-5618.8%#6-52.9%#9——-87.6%#11—
ALXOALX ONCOLOGY HOLDINGS INC$176M#2—1.3x#7——24.6%#6—-74.7%#11-84.4%#3—-17.8%#7—
CNTNCanton Strategic Holdings, Inc.$170M#3—0.4x#1——-194.5%#14—-7.9%#5——-27.1%#8—
SION$169M#4—0.6x#2——-22.0%#12—-28.3%#6————
ANTXAN2 Therapeutics, Inc.$168M#5—2.2x#10——31.5%#3—-46.3%#7——269.0%#1—
ORMPORAMED PHARMACEUTICALS INC.$168M#61.0x#20.8x#584.2x#6—573.1%#1-754.4%#50.0%#2-4.4%#1—70.5%#3—
CURXCuranex Pharmaceuticals Inc$168M#7—35.1x#15——-1068.8%#15—-88.2%#13——-61.2%#10—
MBRXMoleculin Biotech, Inc.$158M#90.6x#113.6x#13——28.8%#4—289.6%#1——-96.5%#13—
MGNXMACROGENICS INC$156M#10—3.6x#111.0x#1-0.3%#4-11.4%#10-48.7%#1-0.2%#4——48.8%#4—
CUECue Biopharma, Inc.$154M#11—66.7x#165.6x#2195.7%#134.6%#2-96.7%#2-1151.6%#16——-5.8%#6—
KRSAKorsana Biosciences, Inc.$147M#12—28.9x#1470.9x#53.7%#3-15.4%#11-239.8%#3-69.4%#10-69.1%#2—139.9%#2—
RNAAtrium Therapeutics, Inc.$145M#13—0.7x#4————0.0%#3——-87.9%#12—
PYXS$142M#14—12.4x#1210.3x#3-14.2%#5-3.0%#9-609.2%#4-696.0%#15————
ZNTLZentalis Pharmaceuticals, Inc.$135M#15—0.9x#6—-100.0%#617.4%#7—-95.4%#14——26.8%#5—
SPRB$131M#16—1.6x#9—-100.0%#626.5%#5—-46.5%#8————

Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.

Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice

PEPG's peers

UPBALXOCNTNSIONANTXORMPCURXMBRXMGNXCUEKRSARNAPYXSZNTLSPRB
← PEPG overview